Get the Stockscreener App
7.4109
1.19%
-0.0891
After Hours:
7.41
-0.0009
-0.01%
Daxor Corporation stock is traded at $7.4109, with a volume of 2,392.
It is down -1.19% in the last 24 hours and down -7.02% over the past month.
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.
See More
Previous Close:
$7.50
Open:
$7.65
24h Volume:
2,392
Relative Volume:
0.35
Market Cap:
$39.23M
Revenue:
$2.61M
Net Income/Loss:
$1.69M
P/E Ratio:
24.68
EPS:
0.3003
Net Cash Flow:
-
1W Performance:
-4.99%
1M Performance:
-7.02%
6M Performance:
-18.83%
1Y Performance:
-22.91%
1-Day Range:
$7.346
$7.6519
1-Week Range:
$7.346
$8.2499
52-Week Range:
$6.55
$10.00
Daxor Corporation Stock (DXR) Company Profile
Name
Daxor Corporation
Sector
Industry
Phone
212-330-8500
Address
Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY
Compare DXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXR
Daxor Corporation
|
7.4109 | 39.23M | 2.61M | 1.69M | 0 | 0.3003 |
|
ISRG
Intuitive Surgical Inc
|
482.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
198.71 | 59.07B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.54 | 44.80B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
212.91 | 31.51B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.51 | 15.75B | 3.90B | 392.30M | 288.10M | 1.95 |
Daxor Corporation Stock (DXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-16-19 | Initiated | Ascendiant Capital Markets | Buy |
Daxor Corporation Stock (DXR) Latest News
Daxor Corporation to Showcase Innovative Blood Volume - GlobeNewswire
Daxor (DXR) to Exhibit at MedAxiom CV Transforum Spring'25 Conference | DXR Stock News - GuruFocus
Daxor to showcase blood volume analysis at Cardiovascular Transforum conference - TipRanks
Revolutionary Blood Volume Technology Slashes Mortality Rates by 82%Groundbreaking Clinical Results Unveiled - Stock Titan
Daxor announces new data at ACC on blood volume analysis - TipRanks
Daxor (DXR) Unveils Promising Heart Failure Study Results at ACC Conference | DXR Stock News - GuruFocus
Breakthrough Heart Failure Study: Daxor BVA Test Doubles Patient Survival Rates - Stock Titan
Daxor (DXR) Submits Next-Gen Blood Analyzer to FDA for Approval - GuruFocus
Daxor submits new blood volume analyzer to FDA By Investing.com - Investing.com South Africa
Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer - marketscreener.com
Daxor submits new blood volume analyzer to FDA - Investing.com
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer - GlobeNewswire
Revolutionary Blood Volume Analyzer With Military Backing Advances Toward FDA Green Light - Stock Titan
CEO’s Bold Move: Major Investment in Daxor Stock - TipRanks
Daxor CEO Michael Feldschuh purchases over $16,000 in stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases over $16,000 in stock - Investing.com Australia
DAXOR CEO Michael Richard Feldschuh Buys 2,063 Shares - TradingView
Where are the Opportunities in (DXR) - news.stocktradersdaily.com
Daxor Corporation (NASDAQ:DXR) Q4 2024 Earnings Call Transcript - MSN
Daxor (NYSEAMERICAN:DXR) Stock Passes Above 200-Day Moving Average – Here’s Why - Defense World
Daxor announces new data from Duke University on BVA at ACC - TipRanks
Daxor’s BVA technology gains traction at cardiology event - Investing.com
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo - GlobeNewswire
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology's 74th Annual Scientific Session and Expo - The Manila Times
Duke Research Reveals Why Daxor's Blood Test Outperforms Traditional Heart Failure Methods - Stock Titan
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks - GlobeNewswire
Daxor Expands to 3 New Locations in New Jersey, Midwest - MarketScreener
Breakthrough Blood Volume Tech With 98% Accuracy Gains Major Healthcare Adoption - Stock Titan
Daxor CEO Michael Feldschuh purchases $8,130 in company shares - Investing.com
Daxor CEO Michael Feldschuh purchases $8,130 in company shares By Investing.com - Investing.com UK
Daxor CEO Feldschuh buys shares worth $5,273 By Investing.com - Investing.com Canada
Daxor CEO Feldschuh buys shares worth $5,273 - Investing.com
Ascendiant Capital Markets Issues Positive Forecast for Daxor (NASDAQ:DXR) Stock Price - The AM Reporter
Daxor (NASDAQ:DXR) Given New $25.00 Price Target at Ascendiant Capital Markets - Defense World
(DXR) Investment Analysis and Advice - Stock Traders Daily
Daxor Corporation Reports Strong 2024 Financial Growth - TipRanks
Daxor CFO Michel Robert J purchases $8,000 in company stock By Investing.com - Investing.com South Africa
Daxor CEO Michael Feldschuh purchases $25,804 in company stock - Investing.com
Daxor CFO Michel Robert J purchases $8,000 in company stock - Investing.com
Daxor Corporation Reports Robust Growth in Earnings Call - TipRanks
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth - Investing.com India
Earnings call transcript: Daxor Q4 2024 sees 116.5% revenue growth By Investing.com - Investing.com UK
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewswire
Daxor Corporation Reports Increase in NAV to $7.25 Per - GlobeNewswire
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 - Yahoo Finance
Daxor Corporation to Host Investor Conference Call to - GlobeNewswire
Daxor Corporation Stock (DXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Daxor Corporation Stock (DXR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Michel Robert J | Chief Financial Officer |
Mar 10 '25 |
Buy |
8.00 |
1,000 |
8,000 |
17,050 |
| Feldschuh Michael Richard | Chief Executive Officer |
Mar 10 '25 |
Buy |
7.68 |
3,360 |
25,805 |
210,852 |
0.90%
3.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):